Tempus AI (NASDAQ:TEM) Given New $95.00 Price Target at HC Wainwright

Tempus AI (NASDAQ:TEM) had its price target raised by HC Wainwright from $89.00 to $95.00 in a research report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Other analysts also recently issued reports about the company. Mizuho began coverage on Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target for the company. Robert W. Baird initiated coverage on Tempus AI in a report on Tuesday, February 17th. They set an “outperform” rating and a $59.00 target price for the company. Canaccord Genuity Group reduced their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research report on Monday, December 22nd. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research note on Wednesday, February 25th. Finally, Piper Sandler lowered their price target on shares of Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $78.62.

Tempus AI Price Performance

Tempus AI stock opened at $52.32 on Monday. The company has a market capitalization of $9.35 billion, a price-to-earnings ratio of -37.11 and a beta of 5.29. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. Tempus AI has a 12 month low of $36.22 and a 12 month high of $104.32. The stock’s 50 day moving average is $59.96 and its 200-day moving average is $72.41.

Insider Buying and Selling at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 2,902 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $171,363.10. Following the completion of the transaction, the chief accounting officer owned 41,159 shares of the company’s stock, valued at approximately $2,430,438.95. The trade was a 6.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO James William Rogers sold 10,084 shares of the stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $59.05, for a total transaction of $595,460.20. Following the completion of the transaction, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at $5,973,852.30. This trade represents a 9.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 590,109 shares of company stock worth $37,056,566 over the last quarter. 26.27% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Tempus AI

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Cranbrook Wealth Management LLC bought a new position in Tempus AI in the 3rd quarter valued at approximately $25,000. JPL Wealth Management LLC bought a new stake in shares of Tempus AI during the third quarter worth $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Tempus AI during the fourth quarter worth $27,000. GAMMA Investing LLC acquired a new position in shares of Tempus AI during the third quarter worth $28,000. Finally, Allworth Financial LP lifted its stake in shares of Tempus AI by 5,000.0% in the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after acquiring an additional 450 shares during the last quarter. 24.22% of the stock is owned by institutional investors.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.